Alector Obtains $29,500,000 Series D Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e3f447be-fb93-478f-adde-a8b028c82a71 - Date
1/7/2016 - Company Name
Alector - Mailing Address
953 Indiana Street San Francisco, CA 94107 USA - Company Description
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. - Website
http://www.alector.com - Transaction Type
Venture Equity - Transaction Amount
$29,500,000 - Transaction Round
Series D - Proceeds Purposes
These significant financial resources provide Alector the ability to independently advance its promising drug candidates into the clinic and expand our discovery pipeline of candidates for neurodegenerative disorders. - M&A Terms
- Venture Investor
Dementia Discovery Fund - Venture Investor
Amgen Ventures - Venture Investor
AbbVie Biotech Ventures - Venture Investor
Merck Capital Ventures - Venture Investor
OrbiMed - Venture Investor
Polaris Partners - Venture Investor
GV - Venture Investor
Topspin Partners - Venture Investor
Mission Bay Capital
